Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway

Oncogene

Volumn 30, Issue 21, 2011, Pages 2401-2410

  Au Yeung, C L ^a   Tsang, T Y ^a   Yau, P L ^a   Kwok, T T ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

cervical cancer; HPV 16 E6; miR 23b; p53; uPA

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 E6; MESSENGER RNA; MICRORNA; MICRORNA 23B; ONCOPROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; UROKINASE; VIRUS PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CELL MIGRATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

3' UNTRANSLATED REGIONS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICRORNAS; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79957611432     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.613     Document Type: Article

References (33)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22. (Pubitemid 27314632)
2. Bai L, Wei L, Wang J, Li X, He P. (2006). Extended effects of human papillomavirus 16 E6-specific short hairpin RNA on cervical carcinoma cells. Int J Gynecol Cancer 16: 718-729.
3. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T et al. (2008). p53-responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68: 10094-10104.
4. Brummelkamp TR, Bernards R, Agami R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553. (Pubitemid 34408678)
5. Calin GA, Croce CM. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. (Pubitemid 44629897)
6. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004. (Pubitemid 38327724)
7. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752. (Pubitemid 46856245)
8. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. (2008). Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34: 122-136.
9. Davis BN, Hata A. (2009). Regulation of microRNA biogenesis: a miRiad of mechanisms. Cell Commun Signal 7: 18.
10. Diederichs S, Haber DA. (2006). Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 66: 6097-6104.
11. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. (1999). Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135. (Pubitemid 29288493)
12. Esquela-Kerscher A, Slack FJ. (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
13. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. (2006). microRNA expression and function in cancer. Trends Mol Med 12: 580-587. (Pubitemid 44780201)
14. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ et al. (2007). A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
15. Kunz C, Pebler S, Otte J, von der Ahe D. (1995). Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 23: 3710-3717.
16. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY et al. (2008). Altered microRNA expression in cervical carcinomas. Clin Cancer Res 14: 2535-2542.
17. Lui WO, Pourmand N, Patterson BK, Fire A. (2007). Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 67: 6031-6043. (Pubitemid 47037482)
18. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. (2008). Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27: 2575-2582. (Pubitemid 351550884)
19. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527. (Pubitemid 36159887)
20. Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL et al. (2007). Global microRNA profiles in cervical squamous cell carcinoma depend on drosha expression levels. J Pathol 212: 368-377. (Pubitemid 47099013)
21. Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Janicke F et al. (1999). Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol 189: 245-250. (Pubitemid 29448920)
22. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P et al. (2009). MicroRNA-23b mediates urokinase and c-met down-modulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 276: 2966-2982.
23. Scaria V, Jadhav V. (2007). microRNAs in viral oncogenesis. Retrovirology 4: 82.
24. Shetty P, Velusamy T, Bhandary YP, Shetty RS, Liu MC, Shetty S. (2008). Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover. Am J Respir Cell Mol Biol 39: 364-372.
25. Soliman PT, Slomovitz BM, Wolf JK. (2004). Mechanisms of cervical cancer. Drug Discovery Today 1: 253-258. (Pubitemid 41128980)
26. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A et al. (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593. (Pubitemid 47327945)
27. Turner MA, Palefsky JM. (1995). Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes. Clin Exp Metast 13: 260-268.
28. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19. (Pubitemid 29406813)
29. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR et al. (2009). Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15: 637-647.
30. Wu W, Zou M, Brickley DR, Pew T, Conzen SD. (2006). Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol Endocrinol 20: 2304-2314. (Pubitemid 44496403)
31. Zhang B, Pan X, Cobb GP, Anderson TA. (2007). microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12. (Pubitemid 46096921)
32. Zuna RE, Allen RA, Moore WE, Mattu R, Dunn ST. (2004). Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. Mod Pathol 17: 1314-1322. (Pubitemid 39472985)
33. Zur Hausen H. (2002). Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2: 342-350. (Pubitemid 37328947)